Home No significant correlation between ACE Ins/Del genetic polymorphism and COVID-19 infection
Article Publicly Available

No significant correlation between ACE Ins/Del genetic polymorphism and COVID-19 infection

  • Mostafa Saadat ORCID logo EMAIL logo
Published/Copyright: May 9, 2020

To the Editor,

I read with great interest the study by Delanghe and his colleagues entitled “COVID-19 infections are also affected by human ACE1 D/I polymorphism” that was published in Clinical Chemistry and Laboratory Medicine [1]. Angiotensin-converting enzyme (ACE; MIM: 106180) is involved in the conversion of angiotensin I to angiotensin II [2]. The ACE has numerous genetic variations including functional polymorphism of insertion/deletion (Ins/Del) [3]. The Del allele shows higher ACE activity [4]. The authors reported correlation between the frequency of the Del allele of the ACE Ins/Del polymorphism and prevalence and mortality rates of COVID-19 in 33 countries (25 European, three north-African and five Middle East countries). They found that the log-transformed prevalence of COVID-19 and the log-transformed mortality due to COVID-19 in 33 countries (on April 1, 2020) are negatively correlated with the Del allele frequency [1]. It should be noted that very recently the authors reported similar findings based on statistical analysis in 25 European countries [5].

Although the COVID-19 infection was reported from Wuhan, China (at the end of 2019), it was distributed to other countries after a short time, and at present it is a pandemic infection. The pandemic of COVID-19 shows a geographical pattern in its prevalence and mortality. It is self-evident that several factors are involved in its prevalence, fatality and mortality. Different genotypes of several genetic polymorphisms of certain genes, at least in part, might be accounted for susceptibility to COVID-19 infection.

Each gene pool has its own specific frequencies for alleles, genotypes and combinations of genotypes. In the case of polymorphic linked loci, gene pools reveal much more differences with each other. If the risk of COVID-19 infection is to be associated with some polymorphic loci, then it is expected that populations will show different patterns for epidemiological parameters.

However, I have some comments on the aforementioned study. First, the authors reported negative correlations between the ACE Del allele with the prevalence and mortality of COVID-19 [1], [5]. It should be noted that based on previous studies the Del allelic frequencies in eastern Asian populations, such as in Chinese, Korean, Taiwanese and Japanese, are lower than in European populations [6]. If there is an inverse relationship between the allelic frequency of Del and the prevalence of COVID-19, the prevalence and mortality of the disease in Eastern Asians are expected to be higher than in European populations. Interestingly, the prevalence and mortality of COVID-19 in these countries are extremely low (please see COVID-19 Coronavirus Pandemic data presented at the website: https://www.worldometers.info/coronavirus/#countries), which reveal a strong disagreement with the aforementioned studies [1], [5]. If data of Asian and European countries were used for analysis, it seems that we would observe no correlation between the ACE Ins/Del polymorphism and the prevalence of COVID-19 infection or the mortality due to COVID-19.

Second, the Del allele has a frequency of about 51%–66% among Europeans, whereas the prevalence of COVID-19 infection or COVID-19-associated mortality shows much higher differences between European countries. The authors supposed that about 38% of the variability of the prevalence can be explained by the relative frequency of the Del allele [5]. It should be noted that the study has an ecologic study design and such conclusion is not correct and is an example of ecologic fallacy.

Third, in addition to hereditary factors that can affect the prevalence, fatality and mortality of a disease, various environmental and social factors are also involved. Regarding the COVID-19 infection, we should consider the economic situation and the level of health services in different countries. For example, in some countries, laboratory tests were extensively used to identify infected persons, while in some other countries very few tests have been performed. It should be noted that in Algeria, Egypt and Tunisia, 148, 879 and 1596 tests per 106 individuals have been performed, respectively, whereas 34059, 33747, 29473 and 26293 tests per 106 individuals were performed in Estonia, Cyprus, Portugal and Switzerland, respectively (on April 24, 2020). The reported prevalence (and also mortality) from a country may be affected by the proportion of performed laboratory diagnostic tests, which is highly dependent on the economic power of the country. These two factors (country income and number of tests per 106 people) show significant differences between countries and might act as confounding factors in the study of relationship between the Del allelic frequency and the prevalence or mortality of COVID-19. Therefore, these important variables should be included in the statistical model. Taken together, the results presented by Delanghe and his colleagues should be interpreted with caution.

Acknowledgments

The author is indebted to Dr. Maryam Ansari-Lari (Shiraz University) for her critical reading of the manuscript.

  1. Research funding: This study was supported by Shiraz University, Iran.

  2. Author contributions: The author has accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: The author states no conflict of interest.

References

1. Delanghe JR, Speeckaert MM, De Buyzere ML. COVID-19 infections are also affected by human ACE1 D/I polymorphism. Clin Chem Lab Med 2020;58:1125–6.10.1515/cclm-2020-0425Search in Google Scholar PubMed

2. Masuyer G, Yates CJ, Sturrock ED, Acharya KR. Angiotensin-I converting enzyme (ACE): structure, biological roles, and molecular basis for chloride ion dependence. Biol Chem 2014;395:1135–49.10.1515/hsz-2014-0157Search in Google Scholar PubMed

3. Fogarty DG, Maxwell AP, Doherty CC, Hughes AE, Nevin NC. ACE gene typing. Lancet 1994;343:851.10.1016/S0140-6736(94)92050-8Search in Google Scholar

4. Suehiro T, Morita T, Inoue M, Kumon Y, Ikeda Y, Hashimoto K. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum Genet 2004;115:91–6.10.1007/s00439-004-1136-4Search in Google Scholar PubMed

5. Delanghe JR, Speeckaert MM, De Buyzere ML. The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. Clin Chim Acta 2020;505:192–3.10.1016/j.cca.2020.03.031Search in Google Scholar PubMed PubMed Central

6. Saab YB, Gard P, Overall A. The geographic distribution of the ACE II genotype: a novel finding. Genet Res 2007;89:259–67.10.1017/S0016672307009019Search in Google Scholar PubMed

Received: 2020-04-24
Accepted: 2020-04-28
Published Online: 2020-05-09
Published in Print: 2020-06-25

©2020 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Critical role of laboratory medicine in the global response to the COVID-19 pandemic
  4. Reviews
  5. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis
  6. COVID-19: progression of disease and intravascular coagulation – present status and future perspectives
  7. IFCC Recommendations
  8. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence
  9. Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations
  10. Opinion Papers
  11. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks
  12. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19)
  13. Laboratory diagnostics within a modular hospital at the time of Coronavirus disease 2019 (COVID-19) in Wuhan
  14. Original Articles
  15. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics
  16. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19)
  17. Routine blood tests as a potential diagnostic tool for COVID-19
  18. Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy
  19. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study
  20. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection
  21. The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019
  22. Letters to the Editor
  23. COVID-19 infections are also affected by human ACE1 D/I polymorphism
  24. No significant correlation between ACE Ins/Del genetic polymorphism and COVID-19 infection
  25. ACE Ins/Del genetic polymorphism and epidemiological findings in COVID-19
  26. Laboratory abnormalities in patients with COVID-2019 infection
  27. Laboratory abnormalities in children with novel coronavirus disease 2019
  28. Clinical laboratory and SARS-CoV-2 infection: where do we stand?
  29. Clinical chemistry tests for patients with COVID-19 – important caveats for interpretation
  30. Antibody tests for COVID-19: drawing attention to the importance of analytical specificity
  31. Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): a pooled analysis
  32. One disease, different features: COVID-19 laboratory and radiological findings in three Italian patients
  33. Decreased “WBC*LYM” was observed in SARS-CoV-2-infected patients from a fever clinic in Wuhan
  34. Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays
  35. Coinfection of SARS-CoV-2 and multiple respiratory pathogens in children
  36. The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene
  37. Potential interference of hydroxychloroquine-glucuronide metabolite on therapeutic drug monitoring of hydroxychloroquine using a mass spectrometry detector
Downloaded on 13.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2020-0577/html
Scroll to top button